Paul Bushdid, Ph.D., joined Southern Research in April 2016 study as director and investigative team leader for the Drug Development division’s Developmental & Reproductive Toxicology (DART) program. Southern Research’s DART program provides a full range of safety evaluation services and Good Laboratory Practice-compliant assessments that determine a chemical’s effects on fertility, fetal development and post-natal outcomes. Bushdid’s team performs complex preclinical studies to ensure that potential medicines, nutraceuticals and environmental chemicals don’t endanger unborn children and pregnant women and don’t negatively affect fertility in men and women.
Prior to joining Southern Research, Bushdid worked for 13 years at global pharmaceutical company GlaxoSmithKline, where he headed an Investigative Developmental Toxicology group. In this role, he managed a team of study directors and technical scientists focusing on teratogens, or agents that can cause birth defects or halt pregnancies. His team was also involved in DART assessments of traditional Chinese medicines, study designs needed for cell and gene therapy products, and data requirements for the use of nanomaterials in non-clinical development.
Bushdid received a doctorate in microbiology and immunology from the Vanderbilt University School of Medicine in 2000, and he served as a post-doctoral fellow at the Cincinnati Children’s Hospital Medical Center before joining GlaxoSmithKline in 2003.